JCI Insight Archives

The study team included, from left, Raymond Harris, MD, J.P. Arroyo, MD, PhD, and Gautam Bhave, MD, PhD.

VUMC researchers upend dogma about vasopressin production

Jan. 5, 2023—Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.

A new mechanism for lupus

Aug. 30, 2022—Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.

Corina Borza, PhD, left, Ambra Pozzi, PhD, and colleagues are studying a certain cell surface receptor’s role in the process that leads to kidney failure.

VUMC study raises hope for improving treatment of kidney disease

Feb. 2, 2022—Vanderbilt research has revealed an important mechanism in the kidney by which a cell surface receptor known as DDR1 fans the flames of inflammation and fibrosis that ultimately lead to kidney failure.

From left, J.Court Reese, Stephanie Moore-Lotridge, PhD, Breanne Gibson, PhD, and Jonathan Schoenecker, MD, PhD, are discovering ways to prevent adverse outcomes in orthopaedic surgery.

Study identifies molecular trigger of severe injury-induced inflammatory response

Jan. 19, 2022—Vanderbilt researchers have discovered that early inappropriate activation of the enzyme plasmin caused by severe injury is a trigger of systemic inflammatory response syndrome and resulting organ failure.

‘Pre-conditioning’ restores immune tolerance

Sep. 16, 2021—A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.

Motor protein linked to intestinal cell differentiation

Aug. 5, 2021—The motor protein MYO5B, a cause of the congenital intestinal disorder microvillus inclusion disease, does more than move cellular cargo, Vanderbilt researchers have discovered.

A “torque” for tumor blood vessels

Aug. 20, 2020—Vanderbilt scientists have discovered a new target for normalizing tumor blood vessels to improve cancer immunotherapies.

Protecting the injured kidney

Jun. 4, 2020—Leslie Gewin and colleagues have upended conventional dogma about Wnt/beta-catenin signaling in the kidney, finding that it protects against chronic kidney disease rather than promoting it.

Team tracks integrin’s role in lung function

Feb. 6, 2020—Beta-1 integrin, a critical component of epithelial extracellular matrix receptors, is essential for normal lung function in adulthood, researchers at VUMC have discovered.

New look at atherosclerosis

Jul. 11, 2019—A new imaging method makes it possible to directly measure cell division and changes in metabolism in atherosclerotic plaques.

Parsing diabetic skin infections

Nov. 29, 2018—Vanderbilt researchers have discovered a role for an inflammatory mediator in diabetic skin infections, suggesting new therapeutic targets for this common complication of diabetes.

VICC study sheds new light on Von Hippel-Lindau syndrome

Mar. 8, 2018—Investigators at Vanderbilt-Ingram Cancer Center (VICC) and the Virginia Tech Carilion Research Institute (VTCRI) have revealed a gene mutation’s role in Von Hippel-Lindau syndrome, a genetically inherited disease which causes tumor growth in several organs.